The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.
Albert Abad
No relevant relationships to disclose
Bartomeu Massuti
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Cristina Gravalos
No relevant relationships to disclose
Pilar Escudero
No relevant relationships to disclose
Carmen Guillen
No relevant relationships to disclose
Jose Luis Manzano
No relevant relationships to disclose
M.Auxiliadora Gomez
No relevant relationships to disclose
Maria Jose Safont
No relevant relationships to disclose
Javier Gallego Plazas
No relevant relationships to disclose
Javier Sastre
No relevant relationships to disclose
Carles Pericay
No relevant relationships to disclose
Rosario Dueñas
No relevant relationships to disclose
Carlos López-López
No relevant relationships to disclose
Ferran Losa
No relevant relationships to disclose
Manuel Valladares Ayerbes
Consultant or Advisory Role - Amgen; Merck
Honoraria - Amgen; Merck
Research Funding - Amgen; Merck
Encarnación González
No relevant relationships to disclose
Ana Yuste
No relevant relationships to disclose
Alfredo Carrato
No relevant relationships to disclose
Enrique Aranda
Consultant or Advisory Role - Merck; Roche